Results of the probabilistic sensitivity analysis
The PSA results are shown in the CEAC in Fig. Cost-effectiveness acceptability curves (CEACs). The cost-effectiveness acceptability frontier shows the probability of two strategies being cost-effective. WTP, willingness-to-pay; P, pembrolizumab; C, chemotherapy; 3GDP, 3-times estimated per capita GDP of ChinaIncremental cost-effectiveness scatter plot distribution (WTP = $38,142.56). Probabilistic sensitivity analysis was performed to test the robustness of the model and address uncertainty in the estimation of model parameters by using 500 Monte Carlo simulations. Most dots were under the WTP threshold ($38,142.56 per QALY), indicating that pembrolizumab probably generated more QALYs with acceptable incremental costs. QALY, quality-adjusted life-year; WTP, willingness-to-pay